Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

January 25, 2024

https://www.globenewswire.com/news-release/2024/01/25/2816683/0/en/Prime-Medicine-Receives-Up-to-15-Million-from-Cystic-Fibrosis-Foundation-to-Advance-Hotspot-and-PASSIGE-Prime-Editors-for-Cystic-Fibrosis.html

CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Cystic Fibrosis Foundation (CF Foundation) has agreed to provide the Company with up to $15 million to support the development of Prime Editors for the treatment of Cystic Fibrosis (CF).

Read more at globenewswire.com

Related news for (PRME)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.